The new PREVENT CVD risk calculator could result in more than 16 million heart patients who are no longer eligible for preventive therapy. These significant changes “carry the potential for both benefit and harm," researchers wrote in JAMA.

A new study of nearly 300 PCI patients suggests biolimus-coated balloons could provide significant value to interventional cardiologists in the years ahead.  

Some care teams have turned to a more active follow-up strategy for high-risk PCI patients—but it may not provide much value. 

Teva Pharmaceuticals has officially launched generic liraglutide injections in the United States. Novo Nordisk currently sells liraglutide under the brand name Victoza.

“While the use of cannabis continues to gain popularity, its broader effects on public health within the general population are not yet fully understood,” one researcher said.

Researchers explored decades of data from more than 25,000 women, sharing their findings in JAMA Network Open.

More than 60% of adults in the United States are expected to have at least one form of cardiovascular disease by 2050, according to new data published by the American Heart Association. Fortunately, evidence does suggest that healthier lifestyles are starting to become more common as time goes on.

“I am proud of this award, particularly because it represents Mount Sinai’s worldwide scientific contributions and dedication to advancements in the cardiovascular field,” Fuster said.